A Plus Biotechnology CoTPE:6918 72 PS Ratio is 2.91 as of Jul. 13, 2026, which is 21% below its 10-year median of 3.69. GuruFocus rates TPE:6918 with a GF Score™ of 72/100 and a GF Value™ of NT$87.24 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks worse than 50.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, A Plus Biotechnology Co's share price is NT$74.10.
A Plus Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$25.45. Hence, A Plus Biotechnology Co's PS Ratio for today is 2.91.
Good Sign:
A Plus Biotechnology Co Ltd stock PS Ratio (=2.92) is close to 3-year low of 2.88.
The historical rank and industry rank for A Plus Biotechnology Co's PS Ratio or its related term are showing as below:
TPE:6918'
s PS Ratio Range Over the Past 10 Years
Min: 2.88 Med: 3.69 Max: 7.87
Current: 2.91
During the past 7 years, A Plus Biotechnology Co's highest PS Ratio was 7.87. The lowest was 2.88. And the median was 3.69.
TPE:6918's PS Ratio is ranked worse than 50.06% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.91
vs TPE:6918: 2.91
During the past 7 years, A Plus Biotechnology Co's highest 3-Year average Revenue per Share Growth Rate was 10.40% per year. The lowest was 5.60% per year. And the median was 8.15% per year.
Back to Basics: PS Ratio
A Plus Biotechnology Co (TPE:6918) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
A Plus Biotechnology Co's Share Price of today is NT$74.10. A Plus Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$25.45.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A Plus Biotechnology Co (TPE:6918) has a PS Ratio of 2.91 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on A Plus Biotechnology Co and its competitors. This is 21% below median its historical median of 3.69. Over the past decade, A Plus Biotechnology Co's PS Ratio has ranged from 2.88 to 7.87. According to the industry distribution chart, A Plus Biotechnology Co ranks #403 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is A Plus Biotechnology Co's PS Ratio too high?
A Plus Biotechnology Co's current PS Ratio of 2.91 is 21% below median its 10-year median of 3.69. Over the past 10 years, this metric has ranged from a low of 2.88 to a high of 7.87. The Medical Devices & Instruments industry median PS Ratio is 2.91. A Plus Biotechnology Co's value of 2.91 is 0% at this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #403 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, A Plus Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #403 out of 805 companies for PS Ratio. This places A Plus Biotechnology Co in the lower half of its industry. The industry median PS Ratio is 2.91. A Plus Biotechnology Co's value of 2.91 is 0% at this benchmark. Historically, A Plus Biotechnology Co's own PS Ratio has ranged from 2.88 to 7.87 over the past decade. While the company's 10-year median is 3.69 vs. the industry median of 2.91, A Plus Biotechnology Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.91, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current PS Ratio of 2.91 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current PS Ratio is 2.91, which is 21% below median its own 10-year median of 3.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.24, compared to a current price of NT$74.10 — trading 15.1% below its estimated fair value. The current PS Ratio is 2.91, which is 21% below median its 10-year median of 3.69 and 0% at the Medical Devices & Instruments industry median of 2.91. A Plus Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current PS Ratio is 2.91 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.10 is trading 15.1% below its estimated GF Value™ of NT$87.24.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
PS Ratio: 2.91 (21% below median its 10-year median of 3.69)
GF Value™: NT$87.24 vs. price of NT$74.10 (15.1% below fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#403 of 805)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
72GF Score
Get the complete analysis for TPE:6918
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
